TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05085418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions CD19/BCMA CAR T-cells
Description: Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
Study: NCT06031818

Intervention type: OTHER
Intervention: The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation
Description: The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will fill in a questionnaire to evaluate the usability of the interpretable framework.

Intervention type: OTHER
Intervention: The model prediction
Description: The radiologist and clinicians will be provided the model prediction results without the explanation of the model and they will be asked to give their own prediction.

Intervention type: OTHER
Intervention: The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation
Description: The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will be asked to give their own prediction.
Study: NCT05886972

Intervention type: BEHAVIORAL
Intervention: Awareness about propofol injection induced pain
Description: The aim of the study is to observe the effect of patient awareness about the possibility of occurrence of pain during propofol injection on the rate of incidence and severity of pain during injection as a primary goal as the pain score of propofol injection pain is the main end point of the study .

Intervention type: BEHAVIORAL
Intervention: Awareness about propofol injection induced pain
Description: The aim of the study is to observe the effect of patient awareness about the possibility of occurrence of pain during propofol injection on the rate of incidence and severity of pain during injection as a primary goal as the pain score of propofol injection pain is the main end point of the study .
Study: NCT05413200

Intervention type: DRUG
Intervention: Isotretinoin
Description: oral isotretinoin with a standard dose regime for 90 days
Study: NCT04996225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobics exercises, Balance exercises
Description: Aerobic exercise, or endurance exercise, is a subdivision of physical exercise that improves cardiovascular and respiratory health. Additionally, it is generally assumed to increase well-being and reduce negative mood states such as anxiety and depression.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aerobics exercises, Balance exercises
Description: Aerobic exercise, or endurance exercise, is a subdivision of physical exercise that improves cardiovascular and respiratory health. Additionally, it is generally assumed to increase well-being and reduce negative mood states such as anxiety and depression.
Study: NCT05770609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 Tablets with Dose A
Description: See Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 Tablets with Dose B
Description: See Arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPH3127 Tablets placebo
Description: See Arm description
Study: NCT05686499

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic Lectures and demonstrations
Description: 1. Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~2. Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didactic Lectures and demonstrations
Description: 1. Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~2. Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors.
Study: NCT05659394

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Wound Care Alone
Description: gold standard compression therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: Stand Wound Care plus IPC
Description: gold standard compression therapy plus IPC (WoundExpress)
Study: NCT04973306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemoradiotherapy
Description: Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.~Radiotherapy: A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 days per week (Radiotherapy was performed on the 2nd, 3rd, 4th, 5th, and 6th day in each cycle, and only 3 times in the 5th cycle)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.~Radiotherapy: A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 days per week (Radiotherapy was performed on the 2nd, 3rd, 4th, 5th, and 6th day in each cycle, and only 3 times in the 5th cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab (200mg/time) was administered intravenously on the 1st and 22nd day.~The intravenous injection lasts about 30 minutes (micropump is recommended, intravenous bolus is prohibited, duration should be not less than 20 minutes and not more than 60 minutes);

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)
Description: After neoadjuvant therapy, patients in groups receive Ivor-Lewis or Mckeown Esophagectomy (Mckeown Esophagectomy recommended)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)
Description: After neoadjuvant therapy, patients in groups receive Ivor-Lewis or Mckeown Esophagectomy (Mckeown Esophagectomy recommended)
Study: NCT05857033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buccal and direct palatal injection with the aid of Buzzy
Description: Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and direct palatal injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buccal and indirect palatal injection with the aid of Buzzy
Description: Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and indirect palatal injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buccal and direct palatal injection without Buzzy
Description: Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and direct palatal injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buccal and indirect palatal injection without Buzzy
Description: Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and indirect palatal injection
Study: NCT05252832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial Cervical Plexus Block
Description: Location of injection for block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltrate
Description: Local infiltration location.
Study: NCT05396001

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LowSalt4Life Application
Description: LowSalt4Life is a dietary sodium intervention mobile application that promotes lower sodium intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LowSalt4Life Application
Description: LowSalt4Life is a dietary sodium intervention mobile application that promotes lower sodium intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-In-time Adaptive Intervention (JITAI)
Description: LowSalt4Life is a dietary sodium application with a just-in-time adaptive intervention (JITAI) component enabled.
Study: NCT06323369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab（neoadjuvant）
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin （neoadjuvant）
Description: Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel （neoadjuvant）
Description: Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection
Description: Standard of care
Study: NCT05737420

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video call
Description: The on-call neurologist can see and communicate with the patient via live stream video-call.
Study: NCT06323369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin（adjuvant）
Description: Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin（adjuvant）
Description: Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab（adjuvant）
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Recommended, standard of care

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Recommended, standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin（neoadjuvant）
Description: Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin（adjuvant）
Description: Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT06380439

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: wrist ankle acupuncture
Description: wrist ankle acupuncture: wrist ankle acupuncture using 0.25 x 25mm filiform needle on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, then covered with 5cm long micropore, retention for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wrist ankle acupuncture
Description: wrist ankle acupuncture: wrist ankle acupuncture using 0.25 x 25mm filiform needle on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, then covered with 5cm long micropore, retention for 4 hours
Study: NCT06323369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin（adjuvant）
Description: Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT06269068

Intervention type: DIAGNOSTIC_TEST
Intervention: Central sensitization inventory
Description: Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.

Intervention type: OTHER
Intervention: Short form-36
Description: Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.

Intervention type: OTHER
Intervention: Oswestry Low Back Pain Disability Questionnaire
Description: With this scale, it is questioned to what extent the patient is affected by low back pain in selected daily living activities under certain ten headings. In total scoring, disability is expressed as a percentage, and high scores are interpreted in favor of an increase in disability.

Intervention type: OTHER
Intervention: Douleur Neuropathique 4
Description: The questionnaire consists of 10 items; while the nature of pain is questioned in 7 items, the other 3 items include brief sensory examination. Patients with a score of 4 or more out of 10 are considered to have neuropathic pain.

Intervention type: OTHER
Intervention: Visual analogue scale
Description: global pain score on a 0 to 10
Study: NCT04338178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Description: This intervention consists of mental exercises aimed at improving executive function via practice. Simple cognitive tasks that encourage reflective learning and insight into patient's own thinking process are administered. Exercises target set-shifting (i.e., cognitive flexibility), estimating, organization and planning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Skills Training (EST)
Description: EST places emphasis on the improvement of inner emotion awareness, facial and body expression recognition and intra- and interpersonal emotion regulation skills. Different modules and interactive exercises are designed to help patients learn about i) the functions and manifestations of emotions, ii) the identification and labelling of own's and others' emotions, iii) tolerating and communicating emotions, and iiii) balancing between negative and positive emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT intervention aimed to manage food craving by teaching group members cognitive (e.g., restructuring of urge-related thoughts) and behavioural strategies (e.g., increasing awareness through food diaries, relaxation skills, identification of cues that trigger craving, avoidance of high-risk situations for craving, distraction).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary outpatient program
Description: Multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches. Patients are regularly followed and educated about the importance of lifestyle changes including healthy dietary habits and exercise in weight reduction and maintenance. Patients are also usually given information about nutritional value of various foods and few simple exercises for decreasing and maintaining body weight. This program is therefore planned as part of the usual care and responds to the recommendations of good practice for obesity
Study: NCT04968509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors and statins with or without ezetimibe
Description: Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).

Intervention type: DRUG
Group type: OTHER
Intervention: Statins with or without ezetimibe
Description: Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
Study: NCT04889768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
Description: 1. HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~2. Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~3. Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~4. After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles.
Study: NCT06470386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alverine
Description: 180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: taken orally, starting dose of 6.25 mg once a day, gradually adjusted according to heart rate to 6.25 mg twice a day, 12.5 mg in the morning and 6.25 mg in the evening, 12.5 mg twice a day, or adjusted to the maximum tolerated dose (heart rate greater than 55 beats/min and systolic blood pressure greater than 90 mmHg), taken continuously for 24 weeks.
Study: NCT04864899

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (CMR)
Description: Imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (CMR)
Description: Imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (CMR)
Description: Imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood investigation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood investigation
Study: NCT04710641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Description: Administered once every 3 weeks on Day 1 of each 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Oral adminstration twice a day
Study: NCT04864899

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood investigation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: Correlating the cardiac MRI parameters with functional capacity

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: Correlating the cardiac MRI parameters with functional capacity

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: Correlating the cardiac MRI parameters with functional capacity
Study: NCT05785728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1202
Description: Administered I.V.
Study: NCT04710641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Oral adminstration twice a day
Study: NCT06083753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPE-307 Dose A
Description: Subjects will receive daily oral doses of PIPE-307
Study: NCT05785728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1202
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1202
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1202
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1202
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1202
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1202
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1202
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1202
Description: Administered I.V.
Study: NCT05350670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perineal massage and cold compress
Description: Using perineal massage and cold compress during the second stage of labor to observe the effect
Study: NCT06199115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: In oncology, photobiomodulation is used to help heal damaged tissues, improve immune response, reduce inflammation, and prevent or treat certain side effects of treatments such as chemotherapy. Photobiomodulation is also the subject of recent clinical studies to expand its indications (peripheral neuropathies induced by certain chemotherapies.~Patients in the experimental group will receive 3 photobiomodulation sessions per week during their oxaliplatin treatments (6 months), for a total of 72 sessions. Exposition to laser light is 30 minutes for each session.
Study: NCT05483985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hera Score
Description: The device uses patient metadata (patient age, day of image capture) and a software algorithm to analyze features of the blastocyst morphology to provide adjunctive information that may predict further development of the embryo to clinical pregnancy after embryo transfer.
Study: NCT05774626

Intervention type: BEHAVIORAL
Intervention: Contraceptive usage
Description: Continued use of injectable contraception, administered on a quarterly basis

Intervention type: BEHAVIORAL
Intervention: Contraceptive usage
Description: Continued use of injectable contraception, administered on a quarterly basis
Study: NCT05678725

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS
Description: used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The stimulation lasted for 20 minutes and included a 10-second ramp-up and 10-second ramp-down.
Study: NCT06083753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPE-307 Dose B
Description: Subjects will receive daily oral doses of PIPE-307

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive daily oral matching dose of Placebo